Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important demonstrating the value to payers and health technology appraisal (HTA) organizations. In a dynamic regulatory and market access landscape, balancing the requirements of regulators and the expectations of payors can be challenging since there is no one-size-fits-all approach.
On May 11, 2023, Precision ADVANCE, the Center for Breakthrough Medicines, and the Alliance for Regenerative Medicine co-sponsored the second annual Cell & Gene Day, hosted by Endpoint News. Throughout this event, over 25 successful innovators from across the advanced therapy sector shared fresh ideas and insights on overcoming critical challenges in bringing life-saving therapies to patients in need. This white paper is based on a discussion moderated by Phil Cyr, Senior Vice President of Precision Value & Health, and the following panelists:*
- Christopher Kurtz, MD, Chief Medical Officer, Kate Therapeutics
Francesca Cook, Vice President, Pricing and Market Access, REGENXBIO
- Oswald Bentinck, Vice President, Global Head of Value & Access, Rocket Pharmaceuticals
- Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion, Orchard Therapeutics